Secukinumab (AIN457) + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Moderate to Severe Plaque-type Psoriasis
Conditions
Moderate to Severe Plaque-type Psoriasis
Trial Timeline
Jun 19, 2012 → Jun 26, 2017
NCT ID
NCT01544595About Secukinumab (AIN457) + Placebo
Secukinumab (AIN457) + Placebo is a phase 3 stage product being developed by Novartis for Moderate to Severe Plaque-type Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT01544595. Target conditions include Moderate to Severe Plaque-type Psoriasis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01752634 | Phase 3 | Completed |
| NCT01770379 | Phase 3 | Terminated |
| NCT01544595 | Phase 3 | Completed |
| NCT01359943 | Phase 2 | Completed |
| NCT01377012 | Phase 3 | Completed |
Competing Products
20 competing products in Moderate to Severe Plaque-type Psoriasis